Synthesis, molecular docking, binding free energy calculation and molecular dynamics simulation studies of benzothiazol-2-ylcarbamodithioates as Staphylococcus aureus MurD inhibitors
A new series of benzothiazol-2-ylcarbamodithioate functional compounds 5a-f has been designed, synthesized and characterized by spectral data. These compounds were screened for their in vitro antibacterial activity against strains of Staphylococcus aureus (NCIM 5021, NCIM 5022 and methicillin-resistant isolate 43300), Bacillus subtilis (NCIM 2545), Escherichia coli (NCIM 2567), Klebsiella pneumoniae (NCIM 2706) and Psudomonas aeruginosa (NCIM 2036). Compounds 5a and 5d exhibited significant activity against all the tested bacterial strains. Specifically, compounds 5a and 5d showed potent activity against K. pneumoniae (NCIM 2706), while compound 5a also displayed potent activity against S. aureus (NCIM 5021). Compound 5d showed minimum IC50 value of 13.37 μM against S. aureus MurD enzyme. Further, the binding interactions of compounds 5a-f in the catalytic pocket have been investigated using the extra-precision molecular docking and binding free energy calculation by MM-GBSA approach. A 30 ns molecular dynamics simulation of 5d/modeled S. aureus MurD enzyme was performed to determine the stability of the predicted binding conformation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of receptor and signal transduction research - 39(2019), 3 vom: 17. Juni, Seite 283-293 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jupudi, Srikanth [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2020 Date Revised 10.02.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/10799893.2019.1663538 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301468664 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301468664 | ||
| 003 | DE-627 | ||
| 005 | 20231225104702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10799893.2019.1663538 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301468664 | ||
| 035 | |a (NLM)31538846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jupudi, Srikanth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, molecular docking, binding free energy calculation and molecular dynamics simulation studies of benzothiazol-2-ylcarbamodithioates as Staphylococcus aureus MurD inhibitors |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2020 | ||
| 500 | |a Date Revised 10.02.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A new series of benzothiazol-2-ylcarbamodithioate functional compounds 5a-f has been designed, synthesized and characterized by spectral data. These compounds were screened for their in vitro antibacterial activity against strains of Staphylococcus aureus (NCIM 5021, NCIM 5022 and methicillin-resistant isolate 43300), Bacillus subtilis (NCIM 2545), Escherichia coli (NCIM 2567), Klebsiella pneumoniae (NCIM 2706) and Psudomonas aeruginosa (NCIM 2036). Compounds 5a and 5d exhibited significant activity against all the tested bacterial strains. Specifically, compounds 5a and 5d showed potent activity against K. pneumoniae (NCIM 2706), while compound 5a also displayed potent activity against S. aureus (NCIM 5021). Compound 5d showed minimum IC50 value of 13.37 μM against S. aureus MurD enzyme. Further, the binding interactions of compounds 5a-f in the catalytic pocket have been investigated using the extra-precision molecular docking and binding free energy calculation by MM-GBSA approach. A 30 ns molecular dynamics simulation of 5d/modeled S. aureus MurD enzyme was performed to determine the stability of the predicted binding conformation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MurD | |
| 650 | 4 | |a IC50 | |
| 650 | 4 | |a antibacterial study | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a molecular dynamics | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Benzothiazoles |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Peptide Synthases |2 NLM | |
| 650 | 7 | |a EC 6.3.2.- |2 NLM | |
| 650 | 7 | |a UDP-N-acetylmuramoylalanine-D-glutamate ligase |2 NLM | |
| 650 | 7 | |a EC 6.3.2.9 |2 NLM | |
| 700 | 1 | |a Azam, Mohammed Afzal |e verfasserin |4 aut | |
| 700 | 1 | |a Wadhwani, Ashish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of receptor and signal transduction research |d 1998 |g 39(2019), 3 vom: 17. Juni, Seite 283-293 |w (DE-627)NLM075607417 |x 1532-4281 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2019 |g number:3 |g day:17 |g month:06 |g pages:283-293 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10799893.2019.1663538 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2019 |e 3 |b 17 |c 06 |h 283-293 | ||